Pyxis Oncology (PYXS) Return on Capital Employed (2021 - 2025)

Pyxis Oncology (PYXS) has 5 years of Return on Capital Employed data on file, last reported at 109.03% in Q4 2025.

• On a quarterly basis, Return on Capital Employed fell 5261.0% year-over-year to 109.03% in Q4 2025; TTM through Dec 2025 was 109.03%, a 5261.0% decrease from a year earlier, with the FY2025 full-year figure at 81.79%, down 2125.0% from the prior year.
• Return on Capital Employed for Q4 2025 stood at 109.03%, up from 111.75% in the prior quarter.
• Over the last five years, Return on Capital Employed for PYXS reached as high as 26.45% in Q1 2022 and fell as low as 111.75% in Q3 2025.
• Historically, Return on Capital Employed has averaged 59.91% across 5 years, with a median of 56.42% in 2024.
• Across the five-year window, Return on Capital Employed soared 3010 bps in 2024 and tumbled 7476 bps in 2025, its largest moves.
• Year by year, Return on Capital Employed stood at 36.49% in 2021, then sank by 82 bps to 66.39% in 2022, then rose by 20 bps to 53.22% in 2023, then retreated by 6 bps to 56.42% in 2024, then slumped by 93 bps to 109.03% in 2025.
• Per Business Quant data, the three most recent Return on Capital Employed figures were 109.03% in Q4 2025, 111.75% in Q3 2025, and 95.19% in Q2 2025.